Alexander I. Bezvodinskikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexander I. Bezvodinskikh has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Natalia A. Totolyan
Pavlov First Saint Petersburg State Medical University
4 shared publications - Yana B. Kushnir
St. Petersburg Pasteur Institute
4 shared publications - Aleksandr Vitalyevich Amelin
Acad. I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Health of Russia
2 shared publications - Anastasiya V. Vladykina
First Saint Petersburg State Medical University named after Academician I.P. Pavlov
2 shared publications - Vladimir S. Krasnov
Pavlov First Saint Petersburg State Medical University
2 shared publications - A. A. Sokolova
Khanty-Mansiysk State Medical Academy; District Clinical Hospital
1 shared publication
Latest Publications
- Open Access
- 19 April 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 114-129
Experience of satralizumab administration in patients with neuromyelitis optica spectrum disorder in the Russian Federation
Introduction . Effectiveness and safety of satralizumab in the treatment of neuromyelitis optica spectrum disorders (NMOSD) have been demonstrated in randomized clinical trials and continue to be evaluated in the real clinical practice (RCP). Aim . To analyze the experience of satralizumab administration in Russian patients with NMOSD in the RCP. Materials and methods . The study was a multicenter retrospective. Analyzed data were taken from outpatient charts/medical records. Baseline clinical and demographic characteristics of patients with results on efficacy and safety of satralizumab treatment were assessed. Results . Data of 71 patients with ages ranging from 12 to 69 years at the start of satralizumab treatment were analyzed. 100% of patients had NMOSD with antibodies to aquaporin-4. At baseline 18.3% of patients were with highly active NMOSD by exacerbation frequency, 69% had previous relapse preventive treatment, 41% received low-dose glucocorticoids. The annualized relapse rate (ARR) during previous 2 years before treatment was 1.26. The median duration of satralizumab therapy was 15 [12; 24.5] months. 58 (82%) patients were relapse-free and included 9 (16%) persons with highly active NMOSD. The ARR decreased to 0.11 over 2 years of therapy (p < 0.001). In 8 (62%) of 13 patients with relapses first attack developed before 6 months of treatment and in 6 (46.2%) cases – during the “clustered period”, 11 (84.6%) patients did not receive low doses glucocorticoids or they were discontinued before 6 months of satralizumab therapy. Adverse events were reported in 19 (26.8%) patients. The neutropenia was the most common. 27 (84.4%) of 32 patients switched from rituximab to satralizumab were relapse-free with a favorable safety. Conclusions . The analysis of the experience on the satralizumab administration in the RCP demonstrated efficacy and favorable safety profile in Russian patients with NMOSD with antibodies to aquaporin-4 aged 12 years and older.
- 19 April 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 114-129
Open AccessExperience of satralizumab administration in patients with neuromyelitis optica spectrum disorder in the Russian Federation
Introduction . Effectiveness and safety of satralizumab in the treatment of neuromyelitis optica spectrum disorders (NMOSD) have been demonstrated in randomized clinical trials and continue to be evaluated in the real clinical practice (RCP). Aim . To analyze the experience of satralizumab administration in Russian patients with NMOSD in the RCP. Materials and methods . The study was a multicenter retrospective. Analyzed data were taken from outpatient charts/medical records. Baseline clinical and demographic characteristics of patients with results on efficacy and safety of satralizumab treatment were assessed. Results . Data of 71 patients with ages ranging from 12 to 69 years at the start of satralizumab treatment were analyzed. 100% of patients had NMOSD with antibodies to aquaporin-4. At baseline 18.3% of patients were with highly active NMOSD by exacerbation frequency, 69% had previous relapse preventive treatment, 41% received low-dose glucocorticoids. The annualized relapse rate (ARR) during previous 2 years before treatment was 1.26. The median duration of satralizumab therapy was 15 [12; 24.5] months. 58 (82%) patients were relapse-free and included 9 (16%) persons with highly active NMOSD. The ARR decreased to 0.11 over 2 years of therapy (p < 0.001). In 8 (62%) of 13 patients with relapses first attack developed before 6 months of treatment and in 6 (46.2%) cases – during the “clustered period”, 11 (84.6%) patients did not receive low doses glucocorticoids or they were discontinued before 6 months of satralizumab therapy. Adverse events were reported in 19 (26.8%) patients. The neutropenia was the most common. 27 (84.4%) of 32 patients switched from rituximab to satralizumab were relapse-free with a favorable safety. Conclusions . The analysis of the experience on the satralizumab administration in the RCP demonstrated efficacy and favorable safety profile in Russian patients with NMOSD with antibodies to aquaporin-4 aged 12 years and older.
- 8 April 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 32 (4)
Laboratory and instrumental diagnostics of chronic inflammatory demyelinating polyneuropathy: analysis of 158 cases
Introduction. Given the diversity of clinical and electrophysiological phenotypes of chronic inflammatory demyelinating polyneuropathy (CIDP) and the variability of their response to disease-modifying therapy, immunopathological mechanisms likely differ across disease forms. Identifying key laboratory and instrumental features of various clinical and pathogenetic variants within the CIDP spectrum remains an important unmet need. The objective was to compare serum and cerebrospinal fluid (CSF) laboratory findings and instrumental study results in typical CIDP and its variants. Methods and materials. This retrospective-prospective study analyzed clinical, laboratory, and instrumental data from 158 patients with definite CIDP meeting the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria, stratified into typical CIDP and CIDP variants. Results. Anti-ganglioside and anti-sulfatide antibodies were most frequently detected in the sensory CIDP variant, in 46.2 % (12/26) of cases. Serum paraprotein was identified in 27.2 % (36/132) of patients; among these, a substantial proportion had the sensory variant – 33 % (12/36). When analyzing the structure of clinical phenotypes among patients screened for the presence of paraprotein (n=132), patients with the distal variant prevailed – 40% (8/20) of cases. The highest protein levels in the cerebrospinal fluid (CSF) were observed in patients with disease onset at the age of 15-29 years (Kruskal–Wallis test, p=0.028), as well as in patients with a relapsing type of course and acute onset (Pearson’s Chi-Square Test, p=0.01). No significant differences in CSF protein levels were found between typical CIDP and CIDP variants. Abnormal CSF oligoclonal IgG patterns were detected in 21.7 % (20/92) of patients and were observed significantly more often in CIDP variants, comprising 60.0 % (12/20) of such cases. According to electroneuromyography (ENMG) data, an increase in distal latency according to n. tibialis was significantly more often recorded in patients with typical CIDP compared with the variants (26.5% vs 7.3%, respectively; Pearson’s Chi-Square Test, p=0.0019). The analysis of cumulative indicators (Σ indicators) for n. tibialis also revealed a higher frequency of pathological changes in patients with typical CIDP (61.2% vs 35.8%; Pearson’s Chi-Square Test, p=0.0033). On magnetic resonance imaging (MRI), accumulation of contrast agent by nerve roots and cerebrospinal nerves was detected in 57.2 % (4/7) of patients with motor CIDP variant, which was significantly more often than in other disease variants (Fisher–Freeman–Halton test, p=0.006). Conclusion. In contemporary practice, laboratory and instrumental diagnostics in CIDP patients plays a critical role in excluding alternative causes of polyneuropathy. The identified laboratory and instrumental features across CIDP variants may be important not only for diagnosis but also for selecting optimal pathogenetic therapy.
- 8 April 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 32 (4)
Laboratory and instrumental diagnostics of chronic inflammatory demyelinating polyneuropathy: analysis of 158 cases
Introduction. Given the diversity of clinical and electrophysiological phenotypes of chronic inflammatory demyelinating polyneuropathy (CIDP) and the variability of their response to disease-modifying therapy, immunopathological mechanisms likely differ across disease forms. Identifying key laboratory and instrumental features of various clinical and pathogenetic variants within the CIDP spectrum remains an important unmet need. The objective was to compare serum and cerebrospinal fluid (CSF) laboratory findings and instrumental study results in typical CIDP and its variants. Methods and materials. This retrospective-prospective study analyzed clinical, laboratory, and instrumental data from 158 patients with definite CIDP meeting the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria, stratified into typical CIDP and CIDP variants. Results. Anti-ganglioside and anti-sulfatide antibodies were most frequently detected in the sensory CIDP variant, in 46.2 % (12/26) of cases. Serum paraprotein was identified in 27.2 % (36/132) of patients; among these, a substantial proportion had the sensory variant – 33 % (12/36). When analyzing the structure of clinical phenotypes among patients screened for the presence of paraprotein (n=132), patients with the distal variant prevailed – 40% (8/20) of cases. The highest protein levels in the cerebrospinal fluid (CSF) were observed in patients with disease onset at the age of 15-29 years (Kruskal–Wallis test, p=0.028), as well as in patients with a relapsing type of course and acute onset (Pearson’s Chi-Square Test, p=0.01). No significant differences in CSF protein levels were found between typical CIDP and CIDP variants. Abnormal CSF oligoclonal IgG patterns were detected in 21.7 % (20/92) of patients and were observed significantly more often in CIDP variants, comprising 60.0 % (12/20) of such cases. According to electroneuromyography (ENMG) data, an increase in distal latency according to n. tibialis was significantly more often recorded in patients with typical CIDP compared with the variants (26.5% vs 7.3%, respectively; Pearson’s Chi-Square Test, p=0.0019). The analysis of cumulative indicators (Σ indicators) for n. tibialis also revealed a higher frequency of pathological changes in patients with typical CIDP (61.2% vs 35.8%; Pearson’s Chi-Square Test, p=0.0033). On magnetic resonance imaging (MRI), accumulation of contrast agent by nerve roots and cerebrospinal nerves was detected in 57.2 % (4/7) of patients with motor CIDP variant, which was significantly more often than in other disease variants (Fisher–Freeman–Halton test, p=0.006). Conclusion. In contemporary practice, laboratory and instrumental diagnostics in CIDP patients plays a critical role in excluding alternative causes of polyneuropathy. The identified laboratory and instrumental features across CIDP variants may be important not only for diagnosis but also for selecting optimal pathogenetic therapy.
- 2 July 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (2)
Neuropathic pain in chronic inflammatory demyelinating polyneuropathies: analysis of 64 cases
Objective. To characterize clinical phenotypes of CIDP with NP, identify possible associations between NP and laboratory parameters, and assess efficacy of pathogenetic and symptomatic therapy. Material and methods. A retrospective-prospective study included 158 patients with CIDP (2021 EAN/PNS criteria). Patients were divided into groups with and without NP, as well as further subcategorized by the timing of NP onset (at disease manifestation or during progression). Results. Neuropathic pain was identified in 64 (40.5%) patients with CIDP. In the NP group, females predominated (male/female ratio=1.21), whereas males were predominant in the non-NP group (male/female ratio = 0.57). There were significant differences in phenotypic structure of CIDP between patients with NP at disease onset, NP following disease progression and those without NP. Sensory variant of CIDP was more frequently associated with NP (50% of cases), while motor phenotype was less commonly associated with pain (6.25% of cases). In all patients with sensory variant of CIDP, NP was the first symptom of disease (n=27). We first analyzed transformation of CIDP phenotypes into typical form. Patients initially presenting with motor phenotype and subsequent NP more often progressed to typical CIDP. Serum paraprotein was more frequently detected in patients with NP (47.0% vs. 26.9% in those without NP). Positive antinuclear factor (ANF) titer (ANF ≥320) in NP patients was significantly associated with rheumatologic diseases. Conclusion. Clinical and laboratory characteristics in patients with neuropathic pain should be considered when selecting optimal therapy.
- 2 July 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (2)
Neuropathic pain in chronic inflammatory demyelinating polyneuropathies: analysis of 64 cases
Objective. To characterize clinical phenotypes of CIDP with NP, identify possible associations between NP and laboratory parameters, and assess efficacy of pathogenetic and symptomatic therapy. Material and methods. A retrospective-prospective study included 158 patients with CIDP (2021 EAN/PNS criteria). Patients were divided into groups with and without NP, as well as further subcategorized by the timing of NP onset (at disease manifestation or during progression). Results. Neuropathic pain was identified in 64 (40.5%) patients with CIDP. In the NP group, females predominated (male/female ratio=1.21), whereas males were predominant in the non-NP group (male/female ratio = 0.57). There were significant differences in phenotypic structure of CIDP between patients with NP at disease onset, NP following disease progression and those without NP. Sensory variant of CIDP was more frequently associated with NP (50% of cases), while motor phenotype was less commonly associated with pain (6.25% of cases). In all patients with sensory variant of CIDP, NP was the first symptom of disease (n=27). We first analyzed transformation of CIDP phenotypes into typical form. Patients initially presenting with motor phenotype and subsequent NP more often progressed to typical CIDP. Serum paraprotein was more frequently detected in patients with NP (47.0% vs. 26.9% in those without NP). Positive antinuclear factor (ANF) titer (ANF ≥320) in NP patients was significantly associated with rheumatologic diseases. Conclusion. Clinical and laboratory characteristics in patients with neuropathic pain should be considered when selecting optimal therapy.
- 24 January 2025
- Published by Alfmed LLC in Medical alphabet
- No. 33,p. 13-18
Chronic inflammatory demyelinating polyneuropathy associated with podocytopathy: a clinical case with literature review
Chronic imflammatory demyelinating polyneuropathy (CIPD) is a heterogenous group of disimmune polyneuropathies, characterised by progressive or relapsing-remitting disease course, with electrophysiologically and pathomorphologically detected peripheral nerve demyelination. Immunotherapy is considered reasonable in CIDP. CIDP associated with antibodies against nodo-paranodal proteins, namely, NF155, CNTN1, Contactin associated protein has been described amongst the rare atypical CIDP subtypes. The detection of antibodies against nodo-paranodal proteins might have a predictive value for a more severe disease course with resistance to corticosteroid and/or IVIG treatment. Herein we report a case of severe relapsing-remitting CIDP, characterized by respiratory muscle weakness requiring assisted ventilation, with a previous history of proteinuria, later also diagnosed with Minimal change disease (MCD).
- 24 January 2025
- Published by Alfmed LLC in Medical alphabet
- No. 33,p. 13-18
Chronic inflammatory demyelinating polyneuropathy associated with podocytopathy: a clinical case with literature review
Chronic imflammatory demyelinating polyneuropathy (CIPD) is a heterogenous group of disimmune polyneuropathies, characterised by progressive or relapsing-remitting disease course, with electrophysiologically and pathomorphologically detected peripheral nerve demyelination. Immunotherapy is considered reasonable in CIDP. CIDP associated with antibodies against nodo-paranodal proteins, namely, NF155, CNTN1, Contactin associated protein has been described amongst the rare atypical CIDP subtypes. The detection of antibodies against nodo-paranodal proteins might have a predictive value for a more severe disease course with resistance to corticosteroid and/or IVIG treatment. Herein we report a case of severe relapsing-remitting CIDP, characterized by respiratory muscle weakness requiring assisted ventilation, with a previous history of proteinuria, later also diagnosed with Minimal change disease (MCD).
- Open Access
- 15 December 2023
- Published by Baltic Medical Education Center in Marine Medicine
- Vol. 9 (4) , 97-106
Clinical cases of “MR-negative” myelopathy amid SARS-CoV-2 infection
INTRODUCTION. Neurological complications are often observed in patients with a new coronavirus infection. Cerebrovascular diseases prevail among them. There is damage to the peripheral nervous system and spinal cord of various kind, including inflammatory and vascular myelopathy. The incidence of myelopathy syndrome among all neurological complications of the new coronavirus infection reaches 3%. OBJECTIVE. To characterize clinical and instrumental features of the rare case – “МR-negative” myelopathy amid SARS-CoV-2 infection. MATERIALS AND METHODS. The article describes a clinical case of myelopathy, associated with COVID-19 without structural changes in the spinal cord on MR-imaging using standard pulse sequences, however, visualized via spinal tractography. CONCLUSION. COVID-19 associated myelopathy is one of the characteristic complications amid the new coronavirus infection. To verify “MR-negative” damage to the central nervous system in COVID-19, advanced protocols of MRI studies might be used, including the promising method – МR-tractography.
- 15 December 2023
- Published by Baltic Medical Education Center in Marine Medicine
- Vol. 9 (4) , 97-106
Open AccessClinical cases of “MR-negative” myelopathy amid SARS-CoV-2 infection
INTRODUCTION. Neurological complications are often observed in patients with a new coronavirus infection. Cerebrovascular diseases prevail among them. There is damage to the peripheral nervous system and spinal cord of various kind, including inflammatory and vascular myelopathy. The incidence of myelopathy syndrome among all neurological complications of the new coronavirus infection reaches 3%. OBJECTIVE. To characterize clinical and instrumental features of the rare case – “МR-negative” myelopathy amid SARS-CoV-2 infection. MATERIALS AND METHODS. The article describes a clinical case of myelopathy, associated with COVID-19 without structural changes in the spinal cord on MR-imaging using standard pulse sequences, however, visualized via spinal tractography. CONCLUSION. COVID-19 associated myelopathy is one of the characteristic complications amid the new coronavirus infection. To verify “MR-negative” damage to the central nervous system in COVID-19, advanced protocols of MRI studies might be used, including the promising method – МR-tractography.